tiprankstipranks
Advertisement
Advertisement

SABS Stock Latest News

SAB Biotherapeutics initiated with an Overweight at Barclays
The FlySAB Biotherapeutics initiated with an Overweight at Barclays
4d ago
SABS
SAB Biotherapeutics Shareholders Back Board and Auditor
PremiumCompany Announcements
SAB Biotherapeutics Shareholders Back Board and Auditor
10d ago
8K
SABS
SAB Biotherapeutics Reaffirmed Buy/High Risk on Regulatory Derisking, Positive SAB-142 Data and Unchanged $11 Price Target
PremiumRatings
SAB Biotherapeutics Reaffirmed Buy/High Risk on Regulatory Derisking, Positive SAB-142 Data and Unchanged $11 Price Target
12d ago
SABS
SAB Biotherapeutics: Buy Rating Reiterated as Tzield Approval De-Risks SAB-142, $10 Price Target Maintained
PremiumRatings
SAB Biotherapeutics: Buy Rating Reiterated as Tzield Approval De-Risks SAB-142, $10 Price Target Maintained
13d ago
SABS
SAB Biotherapeutics initiated with a Buy at Citi
PremiumThe Fly
SAB Biotherapeutics initiated with a Buy at Citi
1M ago
SABS
SAB Biotherapeutics initiated with a Buy at Jefferies
PremiumThe FlySAB Biotherapeutics initiated with a Buy at Jefferies
1M ago
SABS
SAB Biotherapeutics price target raised to $10 from $7 at H.C. Wainwright
Premium
The Fly
SAB Biotherapeutics price target raised to $10 from $7 at H.C. Wainwright
2M ago
SABS
SAB Biotherapeutics Signs Manufacturing Pact for SAB-142
Premium
Company Announcements
SAB Biotherapeutics Signs Manufacturing Pact for SAB-142
2M ago
8K
SABS
Emergent BioSolutions enters SAB-142 development pact with SAB Biotherapeutics
PremiumThe Fly
Emergent BioSolutions enters SAB-142 development pact with SAB Biotherapeutics
2M ago
EBS
SABS
Buy Rating on SABS Driven by SAB-142’s Differentiated T1D Mechanism, Durable C‑Peptide Preservation, and Pivotal SAFEGUARD Catalyst
PremiumRatings
Buy Rating on SABS Driven by SAB-142’s Differentiated T1D Mechanism, Durable C‑Peptide Preservation, and Pivotal SAFEGUARD Catalyst
2M ago
SABS
SAB Biotherapeutics Highlights Positive Phase 1 SAB-142 Results
PremiumCompany Announcements
SAB Biotherapeutics Highlights Positive Phase 1 SAB-142 Results
2M ago
8K
SABS
SAB Biotherapeutics initiated with a Buy at Rodman & Renshaw
PremiumThe Fly
SAB Biotherapeutics initiated with a Buy at Rodman & Renshaw
3M ago
SABS
SABS Upcoming Earnings Report: What to Expect?
PremiumPre-EarningsSABS Upcoming Earnings Report: What to Expect?
3M ago
SABS
SAB Biotherapeutics Launches Major Equity Financing Offering
Premium
Company Announcements
SAB Biotherapeutics Launches Major Equity Financing Offering
3M ago
8K
SABS
SAB Biotherapeutics 19.325M share Spot Secondary priced at $3.85
Premium
The Fly
SAB Biotherapeutics 19.325M share Spot Secondary priced at $3.85
3M ago
SABS
SAB Biotherapeutics $75M Spot Secondary; price range $3.75-$4.07
PremiumThe Fly
SAB Biotherapeutics $75M Spot Secondary; price range $3.75-$4.07
3M ago
SABS
SAB Biotherapeutics announces common stock offering, no amount given
PremiumThe Fly
SAB Biotherapeutics announces common stock offering, no amount given
3M ago
SABS
SAB Biotherapeutics price target raised to $14 from $12 at Chardan
PremiumThe Fly
SAB Biotherapeutics price target raised to $14 from $12 at Chardan
4M ago
SABS
SAB Biotherapeutics Highlights New Phase 1 SAB-142 Data
PremiumCompany Announcements
SAB Biotherapeutics Highlights New Phase 1 SAB-142 Data
4M ago
8K
SABS
SAB Biotherapeutics announces additional Phase 1 data for SAB-142
PremiumThe FlySAB Biotherapeutics announces additional Phase 1 data for SAB-142
4M ago
SABS
Analysts Predict Up to 400% Spike for These 2 ‘Strong Buy’ Penny Stocks
Premium
Stock Analysis & Ideas
Analysts Predict Up to 400% Spike for These 2 ‘Strong Buy’ Penny Stocks
5M ago
ABOS
SABS
SAB Biotherapeutics Updates SAB-142 Roadmap and Funding Outlook
Premium
Company Announcements
SAB Biotherapeutics Updates SAB-142 Roadmap and Funding Outlook
6M ago
8K
SABS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >